NHP Radionuclide Biodistribution Studies: Molecular Imaging For Translational Drug Development

As the biopharmaceutical industry expands beyond conventional small molecules into monoclonal antibodies, antibody-drug conjugates (ADCs), radiopharmaceuticals, cell therapies, gene therapies, and RNA-based medicines, understanding where a therapeutic travels after administration has become a central challenge in drug development.

In recent years, regulatory agencies and drug developers have placed increasing emphasis on biodistribution and target engagement data during preclinical development. This trend is particularly evident in advanced therapeutic modalities such as CAR-T therapies, viral vector-based gene therapies, CNS-targeted biologics, and targeted radioligand therapies, where efficacy and safety are closely linked to tissue-specific distribution.

Traditional pharmacokinetic approaches can quantify circulating drug concentrations, but they often provide limited information about real-time tissue accumulation, target occupancy, and off-target exposure. As a result, radionuclide-based molecular imaging has emerged as a powerful translational tool capable of visualizing drug behavior throughout the body in living subjects.

When combined with non-human primate (NHP) models, molecular imaging offers a highly predictive platform for evaluating biodistribution, pharmacokinetics (PK), pharmacodynamics (PD), and target engagement before clinical trials begin.

Radionuclide biodistribution studies rely on labeling a therapeutic agent with a radioactive isotope that can be detected by PET or SPECT imaging systems.

Following administration, the radiolabeled compound can be monitored non-invasively across multiple organs and tissues over time, allowing researchers to generate quantitative three-dimensional biodistribution maps.

Unlike conventional tissue sampling methods, molecular imaging provides longitudinal information from the same subject, enabling investigators to evaluate:

• Tissue accumulation and clearance kinetics

• Organ-specific exposure

• Blood-brain barrier penetration

• Cellular trafficking and homing

• Receptor occupancy and target engagement

• Off-target distribution patterns

Because PET and SPECT imaging operate at picomolar to femtomolar sensitivity levels, they are particularly valuable for studying biologics and targeted therapies that may accumulate in relatively small anatomical regions.

Historically, biodistribution studies have relied heavily on rodents using tissue homogenization, radioactivity counting, or LC-MS analysis. While these methods remain useful for early discovery, several limitations become apparent when translating data to humans.

Cross-Sectional Rather Than Longitudinal Data

Traditional approaches require sacrificing separate cohorts of animals at each time point, introducing inter-animal variability and preventing continuous monitoring within the same subject.

Limited Anatomical Resolution

The small size of rodent organs makes it difficult to accurately assess regional drug distribution, particularly in the brain, cardiovascular system, and lymphatic tissues.

Species Differences in Target Biology

Many human-specific biologics interact poorly with rodent orthologs. This challenge is especially relevant for:

• Monoclonal antibodies

• Bispecific antibodies

• Cell therapies

• Gene therapies

• Human-specific receptor targets

As a result, rodent biodistribution data may not accurately predict clinical behavior.

Non-human primates offer a unique bridge between preclinical research and human clinical studies. Due to their close genetic, anatomical, and physiological similarity to humans, NHPs enable more clinically relevant biodistribution assessment, particularly for advanced therapeutics.

Key advantages include:

Compatibility with Clinical Imaging Systems

Cynomolgus monkeys can be scanned using the same clinical-grade PET-CT, PET-MRI, SPECT-CT, MRI, and CT systems used in hospitals. This allows direct adoption of clinical imaging protocols and facilitates translational continuity from preclinical studies to human trials.

Longitudinal Dynamic Assessment

Repeated imaging sessions can be performed in the same animal over days or weeks, generating true longitudinal biodistribution data while reducing animal use.

Improved Target Homology

Many therapeutic targets exhibit substantially higher homology between NHPs and humans than between rodents and humans, improving prediction of:

• Tissue exposure

• Receptor binding

• Target occupancy

• Therapeutic response

Quantitative Target Engagement Analysis

By combining therapeutic dosing with receptor-specific radiotracers, researchers can directly measure target occupancy in vivo, generating pharmacodynamic evidence that is often difficult to obtain through conventional approaches.

Several rapidly growing therapeutic areas have accelerated adoption of radionuclide imaging in NHP studies.

Monoclonal Antibodies and ADCs

Long-circulating biologics often require extended monitoring to understand tumor uptake, normal tissue exposure, and potential toxicity. PET isotopes such as zirconium-89 (^89Zr) have become widely used because their physical half-life aligns well with antibody pharmacokinetics.

Cell and Gene Therapies

The success of CAR-T therapies and viral vector-based gene therapies has increased demand for in vivo cell tracking and vector biodistribution studies. Radiolabeling approaches enable direct visualization of:

• Cell homing

• Tissue retention

• Migration patterns

• Off-target localization

CNS Drug Delivery Programs

Demonstrating blood-brain barrier penetration remains a major challenge for neuroscience drug development. PET imaging provides a powerful means of confirming whether therapeutics successfully reach specific brain regions and engage intended targets.

Radiopharmaceutical Development

The rapid growth of theranostics and radioligand therapy has further increased the need for translational biodistribution platforms capable of evaluating both diagnostic and therapeutic isotopes.

Building on its translational imaging infrastructure, Prisys Biotechnologies has established a comprehensive Biodistribution Imaging Service platform integrating isotope labeling, clinical imaging, pharmacology, and quantitative image analysis. The platform is supported by clinical-grade imaging capabilities including PET-CT, MRI, CT, and DSA systems, enabling high-resolution longitudinal assessment in non-human primates.

Isotope Labeling Capabilities

Supported radionuclides include:

PET Isotopes

• ¹⁸F

• ⁶⁴Cu

• ⁶⁸Ga

• ⁸⁹Zr

• ¹²⁴I

SPECT Isotopes

• ⁹⁹mTc

• ¹¹¹In

• ¹²⁵I

• ¹³¹I

These isotopes can be selected based on molecular size, biological half-life, and study objectives.

Advanced Imaging Integration

Prisys integrates PET-derived functional data with high-resolution MRI and CT anatomical imaging, Biodistribution Imaging Service allowing precise localization of radiotracer accumulation within complex tissues such as the CNS, cardiovascular system, and lymphoid organs. The company's imaging platform includes clinical-equivalent MRI, CT, PET-CT, and DSA technologies designed to support translational research.

Representative Translational Applications

Research programs supported by the platform include:

• CNS receptor imaging and target engagement studies

• Cell therapy trafficking and homing assessment

• Antibody biodistribution studies

• CNS delivery verification

• Cardiovascular and metabolic imaging

• Biomarker discovery and validation

NHP radionuclide molecular imaging can support multiple stages of translational development:

• Biodistribution studies for biologics and advanced therapeutics

• PK/PD modeling and dose selection

• Target engagement confirmation

• Blood-brain barrier penetration assessment

• Cell therapy tracking

• Gene therapy vector distribution studies

• Radiopharmaceutical development

• IND-enabling translational packages

By generating clinically relevant imaging biomarkers, these studies can improve confidence in candidate selection and reduce uncertainty before first-in-human trials.

As precision medicine continues to evolve, molecular imaging is expected to play an increasingly important role in translational research.

The convergence of artificial intelligence, quantitative imaging biomarkers, and theranostic development is creating new opportunities to characterize therapeutic behavior in vivo with unprecedented detail.

For next-generation biologics, cell therapies, radioligand therapies, and CNS-targeted medicines, NHP radionuclide biodistribution studies are likely to become a critical component of translational decision-making, helping bridge the gap between promising preclinical findings and successful clinical outcomes.

Contact Prisys Biotech